End stage palliative care of XXXX : a case study.

@entity1 @entity135 @entity137 @entity1161 @entity158 @entity1282 @entity213
BACKGROUND: Locally advanced @entity135 is generally incurable and has a short survival rate. This study aimed to evaluate symptom relief, disease response, and acute @entity137 after palliative hypo-fractionated radiotherapy and long-term survival in affected @entity1 . MATERIALS AND METHODS: Between January 2011 to December 2011, 80 @entity1 who were histopathologically diagnosed as having stage III or stage IV @entity135 and @entity213 based on Eastern Cooperative Oncology Group (ECOG) performance status 1-3, were offered palliative radiotherapy (20 Gy/5Fr/5 Days). Later these @entity1 were evaluated on 30th day after completion of treatment for disease response based on World Health Organisation (WHO) criteria and palliation of symptoms using symptomatic response grading and acute @entity137 by the Radiation Therapy Oncology Group (RTOG). Many @entity1 were given post @entity1161 ( @entity1161 ) palliative chemotherapy for appropriate palliative care and a few @entity1 were selected for further curative @entity1161 . The overall survival was also evaluated among this group of @entity1 with last follow up date of 1st May, 2014. RESULTS: The most common presenting complaint was @entity158 followed by @entity1282 . Most @entity1 (60-70%) had appreciable relief in their presenting symptoms. A good response was observed in the majority following palliative @entity1161 ; a few @entity1 had progressive disease and some had stable and regressed disease. None of the @entity1 experienced radiation @entity137 that required hospital admission. Almost all showed grade one and two acute skin and mucosal @entity137 one month after completion of treatment. The mean survival days for @entity1 given only hypofractionated palliative @entity1161 was 307 days, those with post palliative @entity1161 and palliative chemotherapy was 390 days and @entity1 who went on to receive further palliative @entity1161 and curative @entity1161 dose had significantly overall survival of 582 days. CONCLUSIONS: @entity135 should be identified for suitable palliative hypofractionated radiotherapy to achieve acceptable symptom relief in a great proportion of @entity1 and should be followed by palliative chemotherapy or curative @entity1161 in suitable cases for long-term symptom-free survival.
